AVANOS MEDICAL, INC.

Listed Company

AVNSCIK 0001606498NYSELarge AcceleratedOrthopedic, Prosthetic & Surgical Appliances & SuppliesDelawareFY ends Dec 31

Period

FY 2025

Revenue

$701.20M

Net Income

$-72.90M

Total Assets

$1.07B

Equity

$778.20M

Shares Out

46.50M

Op. Cash Flow

$74.70M

Business

AVANOS MEDICAL, INC. is a medical technology company that develops, manufactures and markets medical device solutions to improve patient outcomes and reduce healthcare costs. The Company offers products for enteral feeding, neonatal and pediatric feeding, non-opioid surgical pain pumps, cold and compression therapy systems, radiofrequency ablation devices, hyaluronic acid injections and related clinical support services. It operates in two principal portfolios—Digestive Health and Pain Management and Recovery—within a single operating and reportable segment. Avanos distributes products globally through hospitals, ambulatory care centers, wholesalers, third-party distributors and strategic distribution partners, and engages with physicians, nurses and group purchasing organizations.

Summary from filing dated 2025-02-26

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net Sales	701	688	673	684	587
Cost of products sold	347	307	294	290	288
Gross Profit	354	381	380	394	299
Research and development	23	26	27	29	31
Selling and general expenses	316	319	335	327	285
Goodwill and intangibles impairment	77	437	0	0	—
Other (income) expense, net	−400,000	−4	13	3	22
Operating (Loss) Income	−62	−396	4	36	−39
Interest income	3	5	3	1	200,000
Interest expense	−8	−12	−15	−10	—
Loss Before Income Taxes	−66	−403	−8	27	−42
Income tax (provision) benefit	−7	17	−2	−5	11
Loss from Continuing Operations	−73	−386	−10	22	−31
Loss from discontinued operations, net of tax	0	−6	−52	29	37
Net Loss	−73	−392	−62	51	6
Continuing operations (in dollars per share)	−1.57	−8.4	−0.21	0.46	−0.64
Discontinued operations (in dollars per share)	0	−0.13	−1.11	0.62	0.77
Basic Loss Per Share (in dollars per share)	−1.57	−8.53	−1.32	1.08	0.13
Continuing operations (in dollars per share)	−1.57	−8.4	−0.21	0.46	−0.64
Discontinued operations (in dollars per share)	0	−0.13	−1.11	0.61	0.77
Diluted Loss Per Share (in dollars per share)	−1.57	−8.53	−1.32	1.07	0.13

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	90	108	88	128	119
Accounts receivable, net of allowances	104	133	143	168	131
Inventories	148	139	163	132	159
Prepaid and other current assets	14	14	29	14	19
Total Current Assets	355	393	487	624	428
Property, Plant and Equipment, net	113	111	117	119	168
Operating Lease Right-of-Use Assets	28	34	27	28	39
Goodwill	395	456	796	760	743
Other Intangible Assets, net	118	112	240	234	141
Deferred Tax Assets	33	25	7	5	10
Other Assets	32	23	19	18	17
TOTAL ASSETS	1,074	1,154	1,692	1,787	1,604
Current portion of long-term debt	10	9	9	6	0
Current portion of operating lease liabilities	8	11	13	12	15
Trade accounts payable	56	54	56	68	56
Accrued expenses	91	91	93	98	68
Total Current Liabilities	165	166	235	191	139
Long-Term Debt	90	125	159	226	130
Operating Lease Liabilities	20	25	28	33	43
Deferred Tax Liabilities	6	6	24	25	12
Other Long-Term Liabilities	14	4	10	21	9
Total Liabilities	296	326	456	496	333
Commitments and Contingencies	—	—	—	—	—
Preferred stock - $0.01 par value - authorized 20,000,000 shares, none issued	0	0	0	0	0
Common stock - $0.01 par value - authorized 300,000,000 shares, 46,456,462 outstanding at December 31, 2025 and 45,962,627 outstanding at December 31, 2024	500,000	500,000	500,000	500,000	500,000
Additional paid-in capital	1,692	1,679	1,664	1,646	1,629
Accumulated deficit	−780	−707	−315	−253	−304
Treasury stock	−102	−99	−86	−67	−21
Accumulated other comprehensive loss	−32	−45	−27	−36	−34
Total Stockholders Equity	778	829	1,236	1,291	1,271
TOTAL LIABILITIES AND STOCKHOLDERS EQUITY	1,074	1,154	1,692	1,787	1,604

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	39	46	46	48	38
Stock-based compensation	13	14	16	16	13
Loss on RH disposal	0	0	71	0	0
Net losses on asset dispositions and asset impairments	9	1	2	1	—
Accounts receivable	31	−7	39	−25	−11
Inventories, net of allowance	200,000	39	5	−31	16
Prepaid expenses and other assets	1	15	−20	3	−2
Accounts payable	600,000	−900,000	−14	35	−12
Accrued expenses	−13	−11	−28	−7	33
Deferred income taxes and other	−10	−39	−22	0	—
Cash Provided by Operating Activities	75	101	32	91	87
Capital expenditures	−32	−18	−18	−19	−21
Proceeds from the sale of assets	4	0	0	—	—
Proceeds from the RH divestiture	0	0	89	0	0
Proceeds from RH divestiture post-closing settlement	0	2	0	0	—
Acquisition of assets and businesses, net of cash acquired	−28	0	−50	−116	0
Investments in non-affiliates	−5	−12	0	0	—
Cash (Used in) Provided by Investing Activities	−61	−28	22	−135	−21
Secured debt repayments	−9	−9	−5	−127	—
Revolving credit facility proceeds	0	20	55	150	20
Revolving credit facility repayments	−25	−45	−115	−170	0
Purchase of treasury stock	−3	−13	−19	−46	−12
Proceeds from the exercise of stock options	700,000	1	1	2	—
Payment of contingent consideration liabilities	0	−4	−12	0	0
Cash Used in Financing Activities	−37	−49	−94	57	−55
Effect of Exchange Rate Changes on Cash and Cash Equivalents	5	−4	200,000	−3	−4
(Decrease) Increase in Cash and Cash Equivalents	−18	20	−40	9	7
Cash paid for income taxes	14	3	24	−3	−45
Cash paid for interest	7	12	15	8	3
Capital expenditures included in accounts payable or accrued expenses	2	6	3	4	6

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro